Streetbeat News

Analyst Ratings

BFAM

Analysts have provided mixed ratings for Bright Horizons Family (NYSE:BFAM) within the last quarter, with an average price target of $84.5, implying a downside compared to the current price of $88.685. The current average has increased by 6.06% from the previous average price target of $79.67.

Portfolio Pulse from Benzinga Insights

June 26, 2023 | 7:01 pm

RLYB

Over the past 3 months, 4 analysts have published their opinions on Rallybio (NASDAQ:RLYB) stock, with an average price target of $17.25, representing a 33.65% decrease from the previous average price target of $26.00. The current price of Rallybio is $6.1775.

Portfolio Pulse from Benzinga Insights

June 26, 2023 | 7:01 pm

LUV

In the last quarter, 4 analysts provided ratings for Southwest Airlines (NYSE:LUV), with an average price target of $47.75, implying an upside from the current price of $34.06. The current average has decreased by 9.48% from the previous average price target of $52.75.

Portfolio Pulse from Benzinga Insights

June 26, 2023 | 7:01 pm

IBM

IBM has received a mix of analyst ratings in the last quarter, with an average 12-month price target of $146.29, representing a 5.11% decrease from the previous average price target of $154.17.

Portfolio Pulse from Benzinga Insights

June 26, 2023 | 7:00 pm

KARO

Over the past 3 months, 4 analysts have published their opinion on Karooooo (NASDAQ:KARO) stock, with all 4 being somewhat bullish. The company has an average 12-month price target of $34.5, which has increased by 2.99% over the past month.

Portfolio Pulse from Benzinga Insights

June 26, 2023 | 7:00 pm

BCE

National Bank of Canada analyst Adam Shine maintains a Sector Perform rating on BCE (TSX:BCE) and lowers the price target from C$63 to C$62.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 6:49 pm

FGEN

B of A Securities analyst Jason Gerberry downgrades FibroGen (NASDAQ:FGEN) from Buy to Neutral and lowers the price target from $29 to $4.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 6:42 pm

LTRN

EF Hutton analyst Michael King maintains a Buy rating on Lantern Pharma (NASDAQ:LTRN) and keeps the $11 price target unchanged.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 6:37 pm

FGEN

Stifel analyst Annabel Samimy downgraded FibroGen (NASDAQ:FGEN) from Buy to Hold and lowered the price target from $28 to $11.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2023 | 6:35 pm